Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years

Cancer Science

Volumn 104, Issue 4, 2013, Pages 465-472

  Yoshikawa, Hiroyuki ^a   Ebihara, Keiko ^b   Tanaka, Yoshiyuki ^b   Noda, Kiichiro ^c  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Merck Sharp Dohm Res Labs Japan   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PLACEBO; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GYNECOLOGICAL RADIOGRAPHY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; JAPANESE; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84875580665     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12106     Document Type: Article

References (32)

1. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-26.
2. Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM. Hand-genital transmission of genital warts? An analysis of prevalence data Epidemiol Infect 1995; 115: 169-76.
3. Herrero R, Castellsagué X, Pawlita M et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-83.
4. Yoshikawa H, Matsukura T, Yoshiike K, Yamamoto E, Kawana T, Mizuno M. Human papillomavirus DNA in female condylomata. Acta Obstet Gynecol Jpn 1985; 37: 1225-30.
5. Infectious Disease Surveillance Center. Annual surveillance data (sentinel-reporting diseases): sexually-transmitted diseases. [Cited 18 Jun 2012.] Available from URL: http://idsc.nih.go.jp/idwr/ydata/report-Jb.html.
6. Tokunaga H, Okamura C, Yaegashi N. Current status and therapeutic strategy of STD HPV, condyloma acuminatum. Obstet Gynecol Pract 2003; 52: 2111-20.
7. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. [Cited 26 Aug 2010.] Available from URL: http://globocan.iarc.fr.
9. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23: 569-78.
10. Ministry of Health, Labour & Walfare. Vital statistics of Japan. [Cited 26 Aug 2010.] Available from URL: http://ganjoho.ncc.go.jp/data/public/statistics/backnumber/1isaao000000068m-att/fig 04.pdf.
11. Patient Survey, Statistics and Information Department, MHLW 1996, 1999 and 2002. [Cited 26 Aug 2010.] Available from URL: http://www.mhlw.go.jp/toukei/list/10-20.html.
12. Mori M, Sagae S. Recent progress in epidemiologic research of uterine cancer. Gan To Kagaku Ryoho 2001; 28: 174-8.
13. Miura S, Matsumoto K, Oki A et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006; 119: 2713-5.
14. Onuki M, Matsumoto K, Satoh T et al. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009; 100: 1312-6.
15. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
16. Ministerial Ordinance on Good Clinical Practice for Drugs. Ordinance of the Ministry of Health and Welfare No. 28 of March 27, 1997. [Cited 13 Feb 2013.] Available from URL: http://www.pmda.go.jp/english/service/pdf/ministerial/20110307No_28.pdf.
17. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-9.
18. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120-9.
19. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 2004; 285: 1500-6.
20. Opalka D, Lachman CE, MacMullen SA, Hall K, Leiserowitz GS. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10: 108-15.
21. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996; 224: 477-86.
22. Christensen ND, Dillner J, Eklund C et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223: 174-84.
23. Wheeler CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-44.
24. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
25. Human Papillomavirus and Related Cancers; Summary Report Update. (JAPAN & WORLD) 15 September 2010. WHO/ICO HPV information centre. [Cited 13 Feb 2013.] Available from URL: http://www.who.int/hpvcentre/en/
26. Christensen ND, Cladel NM, Reed CA et al. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001; 291: 324-34.
27. Dias D, Van Doren J, Schlottmann S et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12: 959-69.
28. Joura EA, Kjaer SK, Wheeler CM et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26: 6844-51.
29. ® vaccinees after 48 mo using a pseudovirion neutralization assay. Hum Vaccin Immunother 2012; 8: 431-4.
30. Olsson SE, Villa LL, Costa RL et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-9.
31. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85: 499-502.
32. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-92.